--- type: "firecrawl-provider" description: "Research payments that drug and device manufacturers and group purchasing organizations reported to CMS under the Physician Payments Sunshine Act (Open Payments): about a million payments a year to teaching hospitals, research institutions and practitioners for clinical trials and other research, each with its sponsor, site, principal investigators, study name and ClinicalTrials.gov ID, products and amount. Search payments, rank them by sponsor, site, investigator, study or product, and read CMS's yearly totals nationally, per manufacturer or per teaching hospital. Program years 2019 to 2025 (published June 2026). Public domain U.S. Government data; every answer carries CMS's attribution, its disclaimer that a reported relationship is not necessarily improper, and its rule for disputed records." use_when: "Research payments that drug and device manufacturers and group purchasing organizations reported to CMS under the Physician Payments Sunshine Act (Open Payments): about a million payments a year to teaching hospitals, research institutions and practitioners for clinical trials and other research, each with its sponsor, site, principal investigators, study name and ClinicalTrials.gov ID, products and amount. Search payments, rank them by sponsor, site, investigator, study or product, and read CMS's yearly totals nationally, per manufacturer or per teaching hospital. Program years 2019 to 2025 (published June 2026). Public domain U.S. Government data; every answer carries CMS's attribution, its disclaimer that a reported relationship is not necessarily improper, and its rule for disputed records." categories: "Life sciences" capabilities: 3 credits_per_call: 5 --- # CMS Open Payments research payments on Firecrawl Alexandria Research payments that drug and device manufacturers and group purchasing organizations reported to CMS under the Physician Payments Sunshine Act (Open Payments): about a million payments a year to teaching hospitals, research institutions and practitioners for clinical trials and other research, each with its sponsor, site, principal investigators, study name and ClinicalTrials.gov ID, products and amount. Search payments, rank them by sponsor, site, investigator, study or product, and read CMS's yearly totals nationally, per manufacturer or per teaching hospital. Program years 2019 to 2025 (published June 2026). Public domain U.S. Government data; every answer carries CMS's attribution, its disclaimer that a reported relationship is not necessarily improper, and its rule for disputed records. - Categories: Life sciences - Category index: [Life sciences category](https://firecrawl.dev/alexandria/agents/categories/life-sciences) - Provider key: `openpaymentsdata-cms-gov` - Access: Firecrawl credits - Cost: 5 credits per call ## More - [Human guide](https://firecrawl.dev/app/alexandria/openpaymentsdata-cms-gov) - [OpenAPI spec](https://firecrawl.dev/alexandria/agents/providers/openpaymentsdata-cms-gov/openapi.json) ## Capabilities - [Search](https://firecrawl.dev/alexandria/agents/providers/openpaymentsdata-cms-gov/research-payments/search): Research payments from CMS Open Payments for one program year (the latest, 2025, by default), largest first, filtered by any of: manufacturer (CMS ID or name), site (teaching hospital CCN, or the name of the hospital or institution paid), investigator (NPI or name of a principal investigator or the practitioner paid), study name, ClinicalTrials.gov ID, product, therapeutic area, recipient state and amount. No filter lists every payment of the year. Each payment has its amount, date and form; the paying manufacturer or GPO; the recipient (teaching hospital, institution or practitioner) with city, state and ZIP; up to five principal investigators with NPI, specialty and location; the study name, ClinicalTrials.gov ID and context; up to five products with type, therapeutic area and NDC; and CMS's dispute and publication flags. `total` counts every match; page with `offset` up to 10,000. No match is an empty result. - [Top](https://firecrawl.dev/alexandria/agents/providers/openpaymentsdata-cms-gov/research-payments/top): Totals of CMS Open Payments research payments for one program year (the latest, 2025, by default), grouped by the paying manufacturer, the recipient, the first principal investigator, the study (with its sponsor) or the first product (with its sponsor), largest total first, after the same filters as search. Each group has its rank, total amount in USD, payment count and its key: the manufacturer's CMS ID, name and location; the recipient's type, name, CCN or NPI and location; the investigator's NPI, CMS profile ID, name, specialty and location; the study name and ClinicalTrials.gov ID; or the product name, type and therapeutic area. `total` counts every group; page with `offset` up to 1,000. No match is an empty result. - [Yearly](https://firecrawl.dev/alexandria/agents/providers/openpaymentsdata-cms-gov/research-payments/yearly): CMS's own yearly Open Payments totals for each program year from 2019: research payment amount and count, general payment amount and count, and records published as disputed. Nationally (no input), for reporting entities matched by CMS ID or name (up to 25), or for teaching hospitals matched by CCN or name, with the sum over the years. Teaching hospital totals count only payments to the hospital itself as a covered recipient: much research money goes to an affiliated institution instead (MD Anderson's mostly to MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS, a non-covered entity), which search and top with `site` include. No match is an empty result. ## 1. Choose this provider when Research payments that drug and device manufacturers and group purchasing organizations reported to CMS under the Physician Payments Sunshine Act (Open Payments): about a million payments a year to teaching hospitals, research institutions and practitioners for clinical trials and other research, each with its sponsor, site, principal investigators, study name and ClinicalTrials.gov ID, products and amount. Search payments, rank them by sponsor, site, investigator, study or product, and read CMS's yearly totals nationally, per manufacturer or per teaching hospital. Program years 2019 to 2025 (published June 2026). Public domain U.S. Government data; every answer carries CMS's attribution, its disclaimer that a reported relationship is not necessarily improper, and its rule for disputed records. ## 2. Minimal request Call `POST https://api.firecrawl.dev/v2/scrape` with `{ alexandria: { provider, capability, options } }`. For a batch, send `{ alexandria: [...] }` with up to 10 calls. ```json { "provider": "openpaymentsdata-cms-gov", "capability": "research-payments/search", "options": { "limit": 5, "manufacturer": "AstraZeneca", "program_year": 2025, "site": "MD Anderson" } } ``` ## 3. Add provider options Use only the options needed for the task: - `investigator` (string): A person on the payment: a 10-digit NPI, a last name (`Jabbour`), or a first and last name (`Elias Jabbour`, `Jabbour, Elias`). Matched against the five principal investigator slots and the physician or practitioner paid directly; the last name exactly (case-insensitive), the first name as a prefix (`Eli` matches ELIAS). Suffixes such as Jr, III, MD or PhD are dropped. Example: `` - `limit` (number): Most results to return. Example: `25` - `manufacturer` (string): The reporting entity (manufacturer or GPO) that made the payment: CMS's 12-digit ID (`100000000146`), or words matched case-insensitively anywhere in an entity's current or former names in CMS's reporting entity profile (`AstraZeneca` matches AstraZeneca Pharmaceuticals LP, AstraZeneca AB and AstraZeneca UK Limited). `manufacturers_matched` lists the entities used. More than 100 matches is invalid_input. Example: `100000000146` - `max_amount` (number): Largest payment amount in USD, inclusive. Example: `10` - `min_amount` (number): Smallest payment amount in USD, inclusive. Example: `10` - `nct_id` (string): A ClinicalTrials.gov ID (`NCT06868277`), matched against the reported ClinicalTrials.gov identifier or anywhere in the study name. Manufacturers often leave the identifier blank, so no match does not mean the trial has no payments; search `study` with the trial's acronym too. Pattern: ^\s*[Nn][Cc][Tt][0-9]{8}\s*$. Example: `NCT06868277` - `offset` (number): Results to skip; pass `next_offset` from the previous page. Example: `0` - `product` (string): Words matched case-insensitively in any of the five product names (drug, biological, device or supply) on the payment (`Imfinzi`, `durvalumab`). Products are named as reported, often by brand. Example: `` - `program_year` (number): Program year, the calendar year the payments were made. Defaults to the latest year CMS has published (2025, published June 30, 2026). CMS keeps the latest seven years online, 2019 to 2025 now; each is its own dataset, so a call covers one year. Example: `2013` - `site` (string): Where the research was paid: a teaching hospital's 6-character CMS Certification Number (`450076`), or words matched case-insensitively anywhere in the teaching hospital or non-covered recipient entity name (`MD Anderson` matches both `Ut Md Anderson Cancer Center` and `MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS`). Sites are named as each manufacturer reported them, so try a short distinctive name. Example: `450076` - `state` (string): Two-letter US state or territory code of the recipient (`TX`). Pattern: ^\s*[A-Za-z]{2}\s*$. Example: `` - `study` (string): Words matched case-insensitively anywhere in the study name as the manufacturer reported it (`ARTEMIDE-Lung04`, `asciminib`). Many manufacturers write the protocol title, some only a protocol number. Example: `ARTEMIDE-Lung04` - `therapeutic_area` (string): Words matched case-insensitively in any product's category or therapeutic area (`oncology`). Example: `` ## 4. Request through your preferred interface ### JavaScript ```javascript const result = await firecrawl.scrape({ alexandria: { provider: "openpaymentsdata-cms-gov", capability: "research-payments/search", options: { limit: 5, manufacturer: "AstraZeneca", program_year: 2025, site: "MD Anderson", }, }, }); ``` ### Python ```python result = firecrawl.scrape_alexandria({ "provider": "openpaymentsdata-cms-gov", "capability": "research-payments/search", "options": { "limit": 5, "manufacturer": "AstraZeneca", "program_year": 2025, "site": "MD Anderson" } }) ``` ### cURL ```sh curl https://api.firecrawl.dev/v2/scrape \ -H "Authorization: Bearer $FIRECRAWL_API_KEY" \ -H "Content-Type: application/json" \ -d '{ "alexandria": { "provider": "openpaymentsdata-cms-gov", "capability": "research-payments/search", "options": { "limit": 5, "manufacturer": "AstraZeneca", "program_year": 2025, "site": "MD Anderson" } } }' ``` ### CLI ```sh firecrawl scrape 'openpaymentsdata-cms-gov/research-payments/search' \ --options '{"limit":5,"manufacturer":"AstraZeneca","program_year":2025,"site":"MD Anderson"}' ``` ### MCP Call the FCX MCP retrieve tool with this object: ```json { "provider": "openpaymentsdata-cms-gov", "capability": "research-payments/search", "options": { "limit": 5, "manufacturer": "AstraZeneca", "program_year": 2025, "site": "MD Anderson" } } ``` Ask for only the returned fields needed by the task. ## 5. Full request shape ```json { "provider": "openpaymentsdata-cms-gov", "capability": "research-payments/search", "options": { "limit": 5, "manufacturer": "AstraZeneca", "program_year": 2025, "site": "MD Anderson" } } ``` ## 6. Response data The response includes `success`, `provider`, `capability`, `creditsCost` and `data`. This example shows the provider payload in `data`: ```json { "data_file_url": "https://download.cms.gov/openpayments/PGYR2025_P06302026_06032026/OP_DTL_RSRCH_PGYR2025_P06302026_06032026.csv", "license": { "attribution": "Source: Centers for Medicare & Medicaid Services (CMS), Open Payments, openpaymentsdata.cms.gov. Use does not imply CMS endorsement.", "disclaimer": "CMS has an impartial role in the collection and reporting of data regarding payments or other transfers of value pursuant to Open Payments. The transparency display of transactions from applicable manufacturers and group purchasing organizations to physicians, physician assistants, advanced practice nurses, and teaching hospitals does not necessarily mean any of the reported financial relationships are improper. All information available on the Open Payments database is open to personal interpretation and if there are questions about the data, patients and their advocates should speak directly to the health care provider for a better understanding.", "disputes": "If an initiated dispute is not resolved by the end of the correction period, the record will be published and identified as disputed. Disputes initiated or resolved after the full 60-day review, dispute, and correction period are not reflected in the initial data publication and will be published as original attested-to data.", "name": "Public domain (U.S. Government work)", "url": "https://www.usa.gov/government-works" }, "manufacturers_matched": [ { "country": "Sweden", "id": "100000000160", "name": "ASTRAZENECA AB", "state": null }, { "country": "United States", "id": "100000000146", "name": "ASTRAZENECA PHARMACEUTICALS LP", "state": "DE" }, { "country": "Great Britain (UK)", "id": "100000010370", "name": "ASTRAZENECA UK LIMITED", "state": null } ], "next_offset": 5, "observed_at_ms": 1793390721824, "offset": 0, "program_year": 2025, "results": [ { "amount_usd": 4812061.6, "change_type": "NEW", "date_of_payment": "2025-01-15", "disputed": false, "expenditure_categories": [], "form_of_payment": "In-kind items and services", "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "JAN", "last_name": "BURGER", "middle_name": "ANDREAS", "npi": "1003901612", "primary_type": "Medical Doctor", "profile_id": "45572", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": true, "name": "CALQUENCE", "ndc": "0310-0512-28", "pdi": null, "therapeutic_area": "Oncology", "type": "Drug" } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185548899", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "Intermittent Therapy with the BTK Inhibitor Acalabrutinib Calquence in Combination with Rituximab to Reduce Toxicity and the Risk of Disease Resistance in Previously Untreated Chronic Lymphocytic Leukemia CLL Patients that are Age 65 YO or Unfit for Intolerant to Ibrutinib Therapy", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" }, { "amount_usd": 4748745, "change_type": "NEW", "date_of_payment": "2025-02-10", "disputed": false, "expenditure_categories": [], "form_of_payment": "In-kind items and services", "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "LUHUA", "last_name": "WANG", "middle_name": null, "npi": "1417042722", "primary_type": "Medical Doctor", "profile_id": "245664", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": true, "name": "CALQUENCE", "ndc": "0310-0512-28", "pdi": null, "therapeutic_area": "Oncology", "type": "Drug" } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185555643", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "A Phase II Study of Acalabrutinib plus rituximab in previously untreated elderly patients with Mantle Cell Lymphoma", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" }, { "amount_usd": 4242212.2, "change_type": "NEW", "date_of_payment": "2025-01-15", "disputed": false, "expenditure_categories": [], "form_of_payment": "In-kind items and services", "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "WILLIAM", "last_name": "WIERDA", "middle_name": "GEORGE", "npi": "1497848279", "primary_type": "Medical Doctor", "profile_id": "248876", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": true, "name": "CALQUENCE", "ndc": "0310-0512-28", "pdi": null, "therapeutic_area": "Oncology", "type": "Drug" } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185538120", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "A Randomized Phase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) ? Early Obinutuzumab (OBIN) for Patients with Chronic Lymphocytic Leukemia (CLL)", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" }, { "amount_usd": 2129938.72, "change_type": "NEW", "date_of_payment": "2025-01-08", "disputed": false, "expenditure_categories": [], "form_of_payment": "Cash or cash equivalent", "manufacturer": { "country": "Great Britain (UK)", "id": "100000010370", "name": "AstraZeneca UK Limited", "state": null }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "PATRICK", "last_name": "PILIE", "middle_name": "GLEN", "npi": "1174818181", "primary_type": "Medical Doctor", "profile_id": "823729", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": false, "name": null, "ndc": null, "pdi": null, "therapeutic_area": null, "type": null } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185550727", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" }, { "amount_usd": 1823144.62, "change_type": "NEW", "date_of_payment": "2025-01-24", "disputed": false, "expenditure_categories": [], "form_of_payment": "Cash or cash equivalent", "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "LUHUA", "last_name": "WANG", "middle_name": null, "npi": "1417042722", "primary_type": "Medical Doctor", "profile_id": "245664", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": true, "name": "CALQUENCE", "ndc": "0310-0512-28", "pdi": null, "therapeutic_area": "Oncology", "type": "Drug" } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185555639", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naive Mantle Cell Lymphoma", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" } ], "source_updated_at": "2026-06-30", "source_url": "https://openpaymentsdata.cms.gov/dataset/f0d1de67-6852-4093-a036-c9328c256a05", "total": 65 } ``` ## API reference-derived contract The following capability contract is generated from the same normalized Alexandria API reference exposed in the API spec. ### Search - Capability: `research-payments/search` - Description: Research payments from CMS Open Payments for one program year (the latest, 2025, by default), largest first, filtered by any of: manufacturer (CMS ID or name), site (teaching hospital CCN, or the name of the hospital or institution paid), investigator (NPI or name of a principal investigator or the practitioner paid), study name, ClinicalTrials.gov ID, product, therapeutic area, recipient state and amount. No filter lists every payment of the year. Each payment has its amount, date and form; the paying manufacturer or GPO; the recipient (teaching hospital, institution or practitioner) with city, state and ZIP; up to five principal investigators with NPI, specialty and location; the study name, ClinicalTrials.gov ID and context; up to five products with type, therapeutic area and NDC; and CMS's dispute and publication flags. `total` counts every match; page with `offset` up to 10,000. No match is an empty result. - Instructions: For "what research payments did AstraZeneca make to MD Anderson in 2025", "which payments name Dr. Jabbour as principal investigator" or "are there payments for study ARTEMIDE-Lung04". For totals by sponsor, site, investigator, study or product use top; for a manufacturer's or hospital's totals across years use yearly. For a trial's registry record use clinicaltrials-gov clinical-trials/study; for a practitioner's NPI record use npiregistry-cms-hhs-gov providers/search. - Cost: 5 credits per call - Capability file: [Search](https://firecrawl.dev/alexandria/agents/providers/openpaymentsdata-cms-gov/research-payments/search) Accepted options: - `investigator` (string): A person on the payment: a 10-digit NPI, a last name (`Jabbour`), or a first and last name (`Elias Jabbour`, `Jabbour, Elias`). Matched against the five principal investigator slots and the physician or practitioner paid directly; the last name exactly (case-insensitive), the first name as a prefix (`Eli` matches ELIAS). Suffixes such as Jr, III, MD or PhD are dropped. Example: `` - `limit` (number): Most results to return. Example: `25` - `manufacturer` (string): The reporting entity (manufacturer or GPO) that made the payment: CMS's 12-digit ID (`100000000146`), or words matched case-insensitively anywhere in an entity's current or former names in CMS's reporting entity profile (`AstraZeneca` matches AstraZeneca Pharmaceuticals LP, AstraZeneca AB and AstraZeneca UK Limited). `manufacturers_matched` lists the entities used. More than 100 matches is invalid_input. Example: `100000000146` - `max_amount` (number): Largest payment amount in USD, inclusive. Example: `10` - `min_amount` (number): Smallest payment amount in USD, inclusive. Example: `10` - `nct_id` (string): A ClinicalTrials.gov ID (`NCT06868277`), matched against the reported ClinicalTrials.gov identifier or anywhere in the study name. Manufacturers often leave the identifier blank, so no match does not mean the trial has no payments; search `study` with the trial's acronym too. Pattern: ^\s*[Nn][Cc][Tt][0-9]{8}\s*$. Example: `NCT06868277` - `offset` (number): Results to skip; pass `next_offset` from the previous page. Example: `0` - `product` (string): Words matched case-insensitively in any of the five product names (drug, biological, device or supply) on the payment (`Imfinzi`, `durvalumab`). Products are named as reported, often by brand. Example: `` - `program_year` (number): Program year, the calendar year the payments were made. Defaults to the latest year CMS has published (2025, published June 30, 2026). CMS keeps the latest seven years online, 2019 to 2025 now; each is its own dataset, so a call covers one year. Example: `2013` - `site` (string): Where the research was paid: a teaching hospital's 6-character CMS Certification Number (`450076`), or words matched case-insensitively anywhere in the teaching hospital or non-covered recipient entity name (`MD Anderson` matches both `Ut Md Anderson Cancer Center` and `MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS`). Sites are named as each manufacturer reported them, so try a short distinctive name. Example: `450076` - `state` (string): Two-letter US state or territory code of the recipient (`TX`). Pattern: ^\s*[A-Za-z]{2}\s*$. Example: `` - `study` (string): Words matched case-insensitively anywhere in the study name as the manufacturer reported it (`ARTEMIDE-Lung04`, `asciminib`). Many manufacturers write the protocol title, some only a protocol number. Example: `ARTEMIDE-Lung04` - `therapeutic_area` (string): Words matched case-insensitively in any product's category or therapeutic area (`oncology`). Example: `` Response schema example: ```json { "data_file_url": "https://download.cms.gov/openpayments/PGYR2025_P06302026_06032026/OP_DTL_RSRCH_PGYR2025_P06302026_06032026.csv", "license": { "attribution": "Source: Centers for Medicare & Medicaid Services (CMS), Open Payments, openpaymentsdata.cms.gov. Use does not imply CMS endorsement.", "disclaimer": "CMS has an impartial role in the collection and reporting of data regarding payments or other transfers of value pursuant to Open Payments. The transparency display of transactions from applicable manufacturers and group purchasing organizations to physicians, physician assistants, advanced practice nurses, and teaching hospitals does not necessarily mean any of the reported financial relationships are improper. All information available on the Open Payments database is open to personal interpretation and if there are questions about the data, patients and their advocates should speak directly to the health care provider for a better understanding.", "disputes": "If an initiated dispute is not resolved by the end of the correction period, the record will be published and identified as disputed. Disputes initiated or resolved after the full 60-day review, dispute, and correction period are not reflected in the initial data publication and will be published as original attested-to data.", "name": "Public domain (U.S. Government work)", "url": "https://www.usa.gov/government-works" }, "manufacturers_matched": [ { "country": "Sweden", "id": "100000000160", "name": "ASTRAZENECA AB", "state": null }, { "country": "United States", "id": "100000000146", "name": "ASTRAZENECA PHARMACEUTICALS LP", "state": "DE" }, { "country": "Great Britain (UK)", "id": "100000010370", "name": "ASTRAZENECA UK LIMITED", "state": null } ], "next_offset": 5, "observed_at_ms": 1793390721824, "offset": 0, "program_year": 2025, "results": [ { "amount_usd": 4812061.6, "change_type": "NEW", "date_of_payment": "2025-01-15", "disputed": false, "expenditure_categories": [], "form_of_payment": "In-kind items and services", "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "JAN", "last_name": "BURGER", "middle_name": "ANDREAS", "npi": "1003901612", "primary_type": "Medical Doctor", "profile_id": "45572", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": true, "name": "CALQUENCE", "ndc": "0310-0512-28", "pdi": null, "therapeutic_area": "Oncology", "type": "Drug" } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185548899", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "Intermittent Therapy with the BTK Inhibitor Acalabrutinib Calquence in Combination with Rituximab to Reduce Toxicity and the Risk of Disease Resistance in Previously Untreated Chronic Lymphocytic Leukemia CLL Patients that are Age 65 YO or Unfit for Intolerant to Ibrutinib Therapy", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" }, { "amount_usd": 4748745, "change_type": "NEW", "date_of_payment": "2025-02-10", "disputed": false, "expenditure_categories": [], "form_of_payment": "In-kind items and services", "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "LUHUA", "last_name": "WANG", "middle_name": null, "npi": "1417042722", "primary_type": "Medical Doctor", "profile_id": "245664", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": true, "name": "CALQUENCE", "ndc": "0310-0512-28", "pdi": null, "therapeutic_area": "Oncology", "type": "Drug" } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185555643", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "A Phase II Study of Acalabrutinib plus rituximab in previously untreated elderly patients with Mantle Cell Lymphoma", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" }, { "amount_usd": 4242212.2, "change_type": "NEW", "date_of_payment": "2025-01-15", "disputed": false, "expenditure_categories": [], "form_of_payment": "In-kind items and services", "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "WILLIAM", "last_name": "WIERDA", "middle_name": "GEORGE", "npi": "1497848279", "primary_type": "Medical Doctor", "profile_id": "248876", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": true, "name": "CALQUENCE", "ndc": "0310-0512-28", "pdi": null, "therapeutic_area": "Oncology", "type": "Drug" } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185538120", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "A Randomized Phase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) ? Early Obinutuzumab (OBIN) for Patients with Chronic Lymphocytic Leukemia (CLL)", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" }, { "amount_usd": 2129938.72, "change_type": "NEW", "date_of_payment": "2025-01-08", "disputed": false, "expenditure_categories": [], "form_of_payment": "Cash or cash equivalent", "manufacturer": { "country": "Great Britain (UK)", "id": "100000010370", "name": "AstraZeneca UK Limited", "state": null }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "PATRICK", "last_name": "PILIE", "middle_name": "GLEN", "npi": "1174818181", "primary_type": "Medical Doctor", "profile_id": "823729", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": false, "name": null, "ndc": null, "pdi": null, "therapeutic_area": null, "type": null } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185550727", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" }, { "amount_usd": 1823144.62, "change_type": "NEW", "date_of_payment": "2025-01-24", "disputed": false, "expenditure_categories": [], "form_of_payment": "Cash or cash equivalent", "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "principal_investigators": [ { "city": "HOUSTON", "country": "United States", "first_name": "LUHUA", "last_name": "WANG", "middle_name": null, "npi": "1417042722", "primary_type": "Medical Doctor", "profile_id": "245664", "specialty": "Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology", "state": "TX", "suffix": null, "type": "Covered Recipient Physician" } ], "products": [ { "covered": true, "name": "CALQUENCE", "ndc": "0310-0512-28", "pdi": null, "therapeutic_area": "Oncology", "type": "Drug" } ], "program_year": 2025, "publication_delayed": false, "published_on": "2026-06-30", "recipient": { "city": "Houston", "country": "United States", "name": "Ut Md Anderson Cancer Center", "npi": null, "primary_type": null, "profile_id": null, "specialty": null, "state": "TX", "teaching_hospital_ccn": "450076", "type": "Covered Recipient Teaching Hospital", "zip_code": "77030" }, "record_id": "1185555639", "related_product": true, "study": { "clinicaltrials_gov_id": null, "context": null, "information_link": null, "name": "A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naive Mantle Cell Lymphoma", "preclinical": false }, "submitted_by": "AstraZeneca Pharmaceuticals LP" } ], "source_updated_at": "2026-06-30", "source_url": "https://openpaymentsdata.cms.gov/dataset/f0d1de67-6852-4093-a036-c9328c256a05", "total": 65 } ``` ### Top - Capability: `research-payments/top` - Description: Totals of CMS Open Payments research payments for one program year (the latest, 2025, by default), grouped by the paying manufacturer, the recipient, the first principal investigator, the study (with its sponsor) or the first product (with its sponsor), largest total first, after the same filters as search. Each group has its rank, total amount in USD, payment count and its key: the manufacturer's CMS ID, name and location; the recipient's type, name, CCN or NPI and location; the investigator's NPI, CMS profile ID, name, specialty and location; the study name and ClinicalTrials.gov ID; or the product name, type and therapeutic area. `total` counts every group; page with `offset` up to 1,000. No match is an empty result. - Instructions: For "which manufacturers paid MD Anderson the most for research", "which investigators did AstraZeneca fund most", "which sites got the most for study X" or "which products drew the most research funding". Payments of several investigators or products count once, under the first one named. For the payments themselves use search; for totals across years use yearly. - Cost: 5 credits per call - Capability file: [Top](https://firecrawl.dev/alexandria/agents/providers/openpaymentsdata-cms-gov/research-payments/top) Accepted options: - `group_by` (string, required): What to total by: the paying `manufacturer`; the `recipient` (teaching hospital, institution or practitioner paid); the first principal `investigator`; the `study` (name and ClinicalTrials.gov ID, with its sponsor); or the first `product` (with its sponsor). Example: `manufacturer` - `investigator` (string): A person on the payment: a 10-digit NPI, a last name (`Jabbour`), or a first and last name (`Elias Jabbour`, `Jabbour, Elias`). Matched against the five principal investigator slots and the physician or practitioner paid directly; the last name exactly (case-insensitive), the first name as a prefix (`Eli` matches ELIAS). Suffixes such as Jr, III, MD or PhD are dropped. Example: `` - `limit` (number): Most results to return. Example: `25` - `manufacturer` (string): The reporting entity (manufacturer or GPO) that made the payment: CMS's 12-digit ID (`100000000146`), or words matched case-insensitively anywhere in an entity's current or former names in CMS's reporting entity profile (`AstraZeneca` matches AstraZeneca Pharmaceuticals LP, AstraZeneca AB and AstraZeneca UK Limited). `manufacturers_matched` lists the entities used. More than 100 matches is invalid_input. Example: `100000000146` - `max_amount` (number): Largest payment amount in USD, inclusive. Example: `10` - `min_amount` (number): Smallest payment amount in USD, inclusive. Example: `10` - `nct_id` (string): A ClinicalTrials.gov ID (`NCT06868277`), matched against the reported ClinicalTrials.gov identifier or anywhere in the study name. Manufacturers often leave the identifier blank, so no match does not mean the trial has no payments; search `study` with the trial's acronym too. Pattern: ^\s*[Nn][Cc][Tt][0-9]{8}\s*$. Example: `NCT06868277` - `offset` (number): Results to skip; pass `next_offset` from the previous page. Example: `0` - `product` (string): Words matched case-insensitively in any of the five product names (drug, biological, device or supply) on the payment (`Imfinzi`, `durvalumab`). Products are named as reported, often by brand. Example: `` - `program_year` (number): Program year, the calendar year the payments were made. Defaults to the latest year CMS has published (2025, published June 30, 2026). CMS keeps the latest seven years online, 2019 to 2025 now; each is its own dataset, so a call covers one year. Example: `2013` - `site` (string): Where the research was paid: a teaching hospital's 6-character CMS Certification Number (`450076`), or words matched case-insensitively anywhere in the teaching hospital or non-covered recipient entity name (`MD Anderson` matches both `Ut Md Anderson Cancer Center` and `MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS`). Sites are named as each manufacturer reported them, so try a short distinctive name. Example: `450076` - `state` (string): Two-letter US state or territory code of the recipient (`TX`). Pattern: ^\s*[A-Za-z]{2}\s*$. Example: `` - `study` (string): Words matched case-insensitively anywhere in the study name as the manufacturer reported it (`ARTEMIDE-Lung04`, `asciminib`). Many manufacturers write the protocol title, some only a protocol number. Example: `ARTEMIDE-Lung04` - `therapeutic_area` (string): Words matched case-insensitively in any product's category or therapeutic area (`oncology`). Example: `` Response schema example: ```json { "data_file_url": "https://download.cms.gov/openpayments/PGYR2025_P06302026_06032026/OP_DTL_RSRCH_PGYR2025_P06302026_06032026.csv", "group_by": "manufacturer", "license": { "attribution": "Source: Centers for Medicare & Medicaid Services (CMS), Open Payments, openpaymentsdata.cms.gov. Use does not imply CMS endorsement.", "disclaimer": "CMS has an impartial role in the collection and reporting of data regarding payments or other transfers of value pursuant to Open Payments. The transparency display of transactions from applicable manufacturers and group purchasing organizations to physicians, physician assistants, advanced practice nurses, and teaching hospitals does not necessarily mean any of the reported financial relationships are improper. All information available on the Open Payments database is open to personal interpretation and if there are questions about the data, patients and their advocates should speak directly to the health care provider for a better understanding.", "disputes": "If an initiated dispute is not resolved by the end of the correction period, the record will be published and identified as disputed. Disputes initiated or resolved after the full 60-day review, dispute, and correction period are not reflected in the initial data publication and will be published as original attested-to data.", "name": "Public domain (U.S. Government work)", "url": "https://www.usa.gov/government-works" }, "manufacturers_matched": null, "next_offset": 10, "observed_at_ms": 1793390721861, "offset": 0, "program_year": 2025, "results": [ { "investigator": null, "manufacturer": { "country": "United States", "id": "100000000228", "name": "Novartis Pharmaceuticals Corporation", "state": "NJ" }, "payments": 95, "product": null, "rank": 1, "recipient": null, "study": null, "total_amount_usd": 44874087.76 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000000337", "name": "Takeda Pharmaceuticals U.S.A., Inc.", "state": "MA" }, "payments": 60, "product": null, "rank": 2, "recipient": null, "study": null, "total_amount_usd": 37941211.06 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000000146", "name": "AstraZeneca Pharmaceuticals LP", "state": "DE" }, "payments": 55, "product": null, "rank": 3, "recipient": null, "study": null, "total_amount_usd": 31213502.61 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000000053", "name": "Merck Sharp & Dohme LLC", "state": "NJ" }, "payments": 98, "product": null, "rank": 4, "recipient": null, "study": null, "total_amount_usd": 26917703.51 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000000203", "name": "Amgen Inc.", "state": "CA" }, "payments": 41, "product": null, "rank": 5, "recipient": null, "study": null, "total_amount_usd": 24167424.33 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000000286", "name": "PFIZER INC.", "state": "NY" }, "payments": 479, "product": null, "rank": 6, "recipient": null, "study": null, "total_amount_usd": 22400607.66 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000005499", "name": "E.R. Squibb & Sons, L.L.C.", "state": "NJ" }, "payments": 74, "product": null, "rank": 7, "recipient": null, "study": null, "total_amount_usd": 18147216.17 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000000204", "name": "ABBVIE INC.", "state": "IL" }, "payments": 862, "product": null, "rank": 8, "recipient": null, "study": null, "total_amount_usd": 16469462.89 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000246816", "name": "SERVIER PHARMACEUTICALS LLC", "state": "MA" }, "payments": 24, "product": null, "rank": 9, "recipient": null, "study": null, "total_amount_usd": 9785321.83 }, { "investigator": null, "manufacturer": { "country": "United States", "id": "100000000069", "name": "Regeneron Pharmaceuticals, Inc.", "state": "NY" }, "payments": 791, "product": null, "rank": 10, "recipient": null, "study": null, "total_amount_usd": 9156996.34 } ], "source_updated_at": "2026-06-30", "source_url": "https://openpaymentsdata.cms.gov/dataset/f0d1de67-6852-4093-a036-c9328c256a05", "total": 121 } ``` ### Yearly - Capability: `research-payments/yearly` - Description: CMS's own yearly Open Payments totals for each program year from 2019: research payment amount and count, general payment amount and count, and records published as disputed. Nationally (no input), for reporting entities matched by CMS ID or name (up to 25), or for teaching hospitals matched by CCN or name, with the sum over the years. Teaching hospital totals count only payments to the hospital itself as a covered recipient: much research money goes to an affiliated institution instead (MD Anderson's mostly to MD ANDERSON CANCER CENTER UNIVERSITY OF TEXAS, a non-covered entity), which search and top with `site` include. No match is an empty result. - Instructions: For "how much did AstraZeneca report in research payments each year", "how much research money did teaching hospital 450076 receive by year" or "how large is Open Payments research spending nationally". For one year's payments use search; for totals by site, investigator or study use top. - Cost: 5 credits per call - Capability file: [Yearly](https://firecrawl.dev/alexandria/agents/providers/openpaymentsdata-cms-gov/research-payments/yearly) Accepted options: - `manufacturer` (string): A reporting entity by CMS's 12-digit ID, or words of its current or former names (up to 25 entities are returned). Example: `` - `program_year` (number): Only this program year; every published year by default. Example: `2013` - `teaching_hospital` (string): A teaching hospital by 6-character CCN (`450076`) or words of its name as CMS lists teaching hospitals (`Md Anderson`). Example: `450076` Response schema example: ```json { "level": "manufacturer", "license": { "attribution": "Source: Centers for Medicare & Medicaid Services (CMS), Open Payments, openpaymentsdata.cms.gov. Use does not imply CMS endorsement.", "disclaimer": "CMS has an impartial role in the collection and reporting of data regarding payments or other transfers of value pursuant to Open Payments. The transparency display of transactions from applicable manufacturers and group purchasing organizations to physicians, physician assistants, advanced practice nurses, and teaching hospitals does not necessarily mean any of the reported financial relationships are improper. All information available on the Open Payments database is open to personal interpretation and if there are questions about the data, patients and their advocates should speak directly to the health care provider for a better understanding.", "disputes": "If an initiated dispute is not resolved by the end of the correction period, the record will be published and identified as disputed. Disputes initiated or resolved after the full 60-day review, dispute, and correction period are not reflected in the initial data publication and will be published as original attested-to data.", "name": "Public domain (U.S. Government work)", "url": "https://www.usa.gov/government-works" }, "observed_at_ms": 1793390721884, "program_year": null, "results": [ { "city": null, "country": "United States", "id": "100000000146", "name": "ASTRAZENECA PHARMACEUTICALS LP", "state": "DE", "total_over_years": { "disputed_records": 10, "general_amount_usd": 455882964.6, "general_payments": 3228979, "research_amount_usd": 2513126992.21, "research_payments": 43708 }, "years": [ { "disputed_records": 1, "general_amount_usd": 72086460.22, "general_payments": 415250, "program_year": 2019, "research_amount_usd": 247631005.15, "research_payments": 7393 }, { "disputed_records": 1, "general_amount_usd": 68404669.41, "general_payments": 309511, "program_year": 2020, "research_amount_usd": 335676452.7, "research_payments": 6549 }, { "disputed_records": 2, "general_amount_usd": 75691974.03, "general_payments": 436207, "program_year": 2021, "research_amount_usd": 397435754.16, "research_payments": 6845 }, { "disputed_records": 6, "general_amount_usd": 48174050.77, "general_payments": 434192, "program_year": 2022, "research_amount_usd": 359327627.87, "research_payments": 5156 }, { "disputed_records": 0, "general_amount_usd": 57247929.3, "general_payments": 464707, "program_year": 2023, "research_amount_usd": 333207047.59, "research_payments": 5201 }, { "disputed_records": 0, "general_amount_usd": 64724186.83, "general_payments": 614064, "program_year": 2024, "research_amount_usd": 363443522.48, "research_payments": 5774 }, { "disputed_records": 0, "general_amount_usd": 69553694.04, "general_payments": 555048, "program_year": 2025, "research_amount_usd": 476405582.26, "research_payments": 6790 } ] } ], "source_updated_at": "2026-06-30", "source_url": "https://openpaymentsdata.cms.gov/dataset/d5762bed-26ca-4035-91c9-9d67297dc77c", "total": 1 } ```